SCHEMBL2963768

SCHEMBL2963768

CSc1ccc(C(N)=O)c(NCCN)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K2 P36507 2/20 0.45
MAP2K1 Q02750 2/20 0.45
SYK P43405 5/20 0.44
MAP4K4 O95819 2/20 0.44
PLK4 O00444 1/20 0.44
CHEK1 O14757 1/20 0.44
DAPK3 O43293 1/20 0.44
PRKD3 O94806 1/20 0.44
PAK4 O96013 1/20 0.44
ABL1 P00519 1/20 0.44
PRKCG P05129 1/20 0.44
FYN P06241 1/20 0.44
CSF1R P07333 1/20 0.44
LYN P07948 1/20 0.44
RET P07949 1/20 0.44
PDGFRB P09619 1/20 0.44
KIT P10721 1/20 0.44
SRC P12931 1/20 0.44
PDGFRA P16234 1/20 0.44
FER P16591 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2963771 0.78 HTR7 (0.36) SYKKDM4CALDH1A1TSHRHSD17B10
SCHEMBL30846815 0.73 DGAT1 (0.55) MAP2K2MAP2K1KMT2AKDM4EMEN1
SCHEMBL21947304 0.73 DGAT1 (0.55) MAP2K2MAP2K1KMT2AKDM4EMEN1
SCHEMBL9650585 0.73 MAP4K4 (0.41) MAP2K2MAP2K1SYKMAP4K4PLK4
SCHEMBL17315235 0.73 AGTR1 (0.53) SYKKMT2AKDM4EMEN1MAPT
SCHEMBL30826508 0.71 MCL1 (0.55) MAP2K2MAP2K1KMT2AKDM4EMEN1
SCHEMBL9102881 0.71 HPGD (0.48) MAP2K2MAP2K1KMT2AKDM4EMEN1
SCHEMBL15638492 0.70 MCL1 (0.44) KMT2AKDM4EMEN1NPC1MAPT
SCHEMBL21843804 0.69 MAP2K2 (0.49) MAP2K2MAP2K1KMT2AKDM4EMEN1
SCHEMBL9419698 0.69 NQO2 (0.47) MAP4K4KMT2AKDM4EMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2510925-B1 Small-Molecule modulators of TRP-P8 activity DENDREON CORP (US) 2016-07-20 EP disclosed
US-8618155-B2 Small-molecule modulators of Trp-p8 activity DENDREON CORPORATION (US) 2013-12-31 US disclosed
US-8614243-B2 Small-molecule modulators of Trp-p8 activity DENDREON CORPORATION (US) 2013-12-24 US disclosed
EP-2510925-A2 Small-Molecule modulators of TRP-P8 activity DENDREON CORPORATION (US) 2012-10-17 EP disclosed
US-20120225871-A1 SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY DENDREON CORPORATION (US) 2012-09-06 US disclosed
US-7772266-B2 treating or preventing benign prostatic hyperplasia, enlarged prostate, acute urinary retention with 2-Isopropyl-5-methyl-cyclohexanecarboxylic acid (2-amino-2-phenyl-ethyl)-amide; agonists or antagonists of a transient receptor potential proteins; anticarcinogenic agent DENDREON CORPORATION (US) 2010-08-10 US disclosed
US-7741355-B2 Small-molecule modulators of TRP-p8 activity DENDREON CORPORATION (US) 2010-06-22 US disclosed
US-20080255185-A1 SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY DENDREON CORPORATION (US) 2008-10-16 US disclosed
US-20070232603-A1 Small-molecule modulators of TRP-P8 activity DENDREON CORPORATION (US) 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232603-A1 Small-molecule modulators of TRP-P8 activity TRPC4, TRPC3, TRPC1 MAP2K2 4630/4885MAP2K1 4626/4885SYK 4370/4885
US-20080255185-A1 SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY TRPC4, TRPC3, TRPC1 MAP2K2 4630/4885MAP2K1 4626/4885SYK 4370/4885
US-20120225871-A1 SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY TRPC4, TRPC3, TRPC1 MAP2K2 4630/4885MAP2K1 4626/4885SYK 4370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.